

Quality of life outcomes after primary treatment for clinically localised prostate cancer: A systematic review

LARDAS, Michael, LIEW, Matthew, VAN DEN BERGH, Roderick C., DE SANTIS, Maria, BELLMUNT, Joaquim, VAN DEN BROECK, Thomas, CORNFORD, Philip, CUMBERBATCH, Marcus G., FOSSATI, Nicola, GROSA, Tobias, HENRY, Ann M., BOLLA, Michel, BRIERS, Erik, JONIAU, Steven, LAM, Thomas B., MASON, Malcolm D., MOTTET, Nicolas, VAN DER POEL, Henk G., ROUVIÈRE, Olivier, SCHOOTS, Ivo G., WIEGEL, Thomas, WILLEMSE, Peter-Paul M., YUAN, Cathy Yuhong and BOURKE, Liam <<http://orcid.org/0000-0002-6548-4603>>

Available from Sheffield Hallam University Research Archive (SHURA) at:

<http://shura.shu.ac.uk/16531/>

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it.

Published version

LARDAS, Michael, LIEW, Matthew, VAN DEN BERGH, Roderick C., DE SANTIS, Maria, BELLMUNT, Joaquim, VAN DEN BROECK, Thomas, CORNFORD, Philip, CUMBERBATCH, Marcus G., FOSSATI, Nicola, GROSA, Tobias, HENRY, Ann M., BOLLA, Michel, BRIERS, Erik, JONIAU, Steven, LAM, Thomas B., MASON, Malcolm D., MOTTET, Nicolas, VAN DER POEL, Henk G., ROUVIÈRE, Olivier, SCHOOTS, Ivo G., WIEGEL, Thomas, WILLEMSE, Peter-Paul M., YUAN, Cathy Yuhong and BOURKE, Liam (2017). Quality of life outcomes after primary treatment for clinically localised prostate cancer: A systematic review. *European Urology*, 72 (6), 869-885.

Copyright and re-use policy

See <http://shura.shu.ac.uk/information.html>

Table 1a: Baseline characteristics of RCTs

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range]	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
Crook 2011 [11], North America, RCT-prospective, 2002-2004 EPIC	Radical prostatectomy	66	61.4 (6.2)	62.4 [38.4 – 78]	NR but inclusion criteria: either T1c or T2a	NR but inclusion criteria: ≤6	5.5 (2.1)	50% *
	Brachytherapy	102	59.4 (5.9)				5.3 (2.8)	40.9% * *% of patients taking medications for Diabetes Mellitus, Hypertension or Cardiovascular disease
Donovan 2016 [12], UK, RCT, 1999-2009 EPIC EORTC QLQ-C30	Active monitoring	545	62 (5)	EORTC QLQ-C30 was assessed at 60 months EPIC was assessed at 72 months	T1c: 410 (75%) T2: 135 (25%)	6: 421 (77%) 7: 111 (20%) 8-10: 13 (2%) Missing: 0	4.7 [3.7-6.7]	NR
	Radical prostatectomy	553	62 (5)		T1c: 410 (74%) T2: 143 (26%)	6: 422 (76%) 7: 120 (22%) 8-10: 10 (2%) Missing: 1	4.9 [3.7-6.7]	
	EBRT	545	62 (5)		T1c: 429 (79%) T2: 116 (21%)	6: 423 (78%) 7: 108 (20%) 8-10: 14 (3%) Missing: 0	4.8 [3.7-6.7]	
Giberti 2009 [13], Italy, RCT, 1999-2002	Radical prostatectomy	100	65.2 [57–74]	68.2 [60–102]	T1c: 64 (64%) T2a: 36 (36%)	5.9	7.8 [3.5-10]	NR

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range]	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
EORTC QLQ-C30 EORTC QLQ-PR25	Brachytherapy	100	65.6 [56-74]		T1c: 59 (59%) T2a: 41 (41%)	5.7	7.5 [2.9-9.3]	

NR: not reported

EBRT: External beam radiotherapy